Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease [1]

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 242-244

  Koscielniak, Ewa ^a   Gross Wieltsch, Ute ^a   Treuner, Joern ^a   Winkler, Peter ^a   Klingebiel, Thomas ^a   Lang, Peter ^a   Bader, Peter ^a   Niethammer, Dietrich ^a   Handgretinger, Rupert ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; IDARUBICIN; OKT 3; THIOTEPA; TROFOSFAMIDE;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANAMNESIS; BONE MARROW METASTASIS; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CASE REPORT; EWING SARCOMA; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HUMAN; LETTER; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHABDOMYOSARCOMA; STEM CELL TRANSPLANTATION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; IMMUNOLOGY; METASTASIS; REMISSION;

ADOLESCENT; FEMALE; GRAFT VS TUMOR EFFECT; HAPLOIDY; HISTOCOMPATIBILITY; HUMANS; NEOPLASM METASTASIS; REMISSION INDUCTION; SARCOMA, EWING'S; STEM CELL TRANSPLANTATION;

EID: 16644398860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.940     Document Type: Letter

References (9)

1. Carli M, Colombatti R, Oberlin O, et al: High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17:2796-2803, 1999
2. Breitfeld PP, Lyden E, Raney RB, et al: Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 23:225-233, 2001
3. Pappo AS, Anderson JR, Crist WM, et al: Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 17:3487-3493, 1999
4. Koscielniak E, Handgretinger R, Dilloo D, et al: Definition of the high risk patients: The EBMT-CWS experience and CWS proposal for a therapeutic strategy for high risk sarcoma patients-EBMT Working Party on Pediatric Diseases 2002. Bone Marrow Transplant 30:533, 2002 (suppl 1)
5. Ueno NT, Rondon G, Mirza NQ, et al: Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986-993, 1998
6. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000
7. Childs RW, Clave E, Tisdale J, et al: Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 17:2044-2049, 1999
8. Eibl B, Schwaighofer H, Nachbaur D, et al: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508, 1996
9. Handgretinger R, Klingebiel T, Lang P, et al: Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27:777-783, 2001